Loading…
Milestone Pharmaceuticals Inc. is projected to rise to $1.34 by 2027, a +21% move from its current price of $1.11. MIST is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.07 | $1.11 | $1.15 | +0.08% |
| Aug 5 | $1.06 | $1.11 | $1.17 | +0.16% |
| Aug 6 | $1.05 | $1.11 | $1.18 | +0.24% |
| Aug 7 | $1.04 | $1.11 | $1.19 | +0.32% |
| Aug 8 | $1.03 | $1.11 | $1.20 | +0.40% |
| Aug 9 | $1.03 | $1.12 | $1.21 | +0.49% |
| Aug 10 | $1.02 | $1.12 | $1.22 | +0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.02 | $1.12 | $1.22 | +0.57% |
| Week 2 | $0.9892 | $1.12 | $1.27 | +1.14% |
| Week 3 | $0.9669 | $1.13 | $1.32 | +1.71% |
| Week 4 | $0.9493 | $1.14 | $1.36 | +2.29% |
| Week 5 | $0.9347 | $1.14 | $1.39 | +2.87% |
| Week 6 | $0.9223 | $1.15 | $1.43 | +3.45% |
| Week 7 | $0.9113 | $1.15 | $1.46 | +4.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.
was incorporated in 2003 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals (MIST) is a biopharmaceutical company focused on cardiovascular medicines in the United States and Canada. It currently trades at $1.15 per share with a market capitalization of $129.48M and is ranked 5309. The price outlook shows a rising trajectory over the forecast horizon, with 2026 averaging $1.15 and 2050 averaging $10.51 with a max of $21.20, accompanied by substantial long‑term ROI potential.
A major floor 22.2% below — a decisive break under it would weaken the trend.
The nearest floor, 6.3% below — buyers have tended to step in here.
The nearest ceiling, 20.7% above — a clean break opens room to run.
A major ceiling 98.2% above — clearing it would confirm fresh momentum.
Key MIST support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MIST market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.10 | Buy | $1.12 | Sell |
| MA 10 | $1.15 | Sell | $1.14 | Sell |
| MA 20 | $1.21 | Sell | $1.19 | Sell |
| MA 50 | $1.28 | Sell | $1.31 | Sell |
| MA 100 | $1.49 | Sell | $1.46 | Sell |
| MA 200 | $1.76 | Sell | $1.61 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.29 | Neutral |
| Stoch RSI (14) | 60.49 | Neutral |
| CCI (20) | -98.36 | Neutral |
| Williams %R (14) | -73.08 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -12.60 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 26.92 | Neutral |
| TRIX (15) | -0.55 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 36.95 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 1.07 | Buy |
| ADX (14) | 23.26 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL with RSI(14) at 40. The stock’s near-term trend is reflected by SMA50 at $1.28 and SMA200 at $1.76, indicating the price is near key moving averages. In the near term, support sits at $1.04 and resistance at $1.34, framing a 30-day range from $0.919 to $1.44.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.01 | $1.11 | $1.60 | 0% | Neutral | |
| $1.04 | $1.34 | $1.83 | +21% | Bullish | |
| $1.08 | $1.44 | $2.05 | +29% | Bullish | |
| $1.13 | $1.54 | $2.28 | +39% | Bullish | |
| $1.29 | $1.82 | $2.76 | +64% | Bullish | |
| $1.52 | $2.19 | $3.42 | +97% | Bullish | |
| $1.74 | $2.57 | $4.10 | +131% | Bullish | |
| $1.90 | $2.86 | $4.67 | +158% | Bullish | |
| $1.76 | $2.71 | $4.50 | +144% | Bullish | |
| $1.83 | $2.86 | $4.83 | +158% | Bullish | |
| $2.56 | $4.39 | $7.97 | +295% | Bullish | |
| $5.36 | $10.78 | $21.69 | +871% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.01 | $1.11 | $1.40 | +0.00% |
| September 2026 | $1.01 | $1.21 | $1.48 | +8.73% |
| October 2026 | $0.9949 | $1.19 | $1.49 | -1.00% |
| November 2026 | $0.9968 | $1.21 | $1.52 | +0.89% |
| December 2026 | $1.03 | $1.26 | $1.60 | +4.26% |
Click any year to see its month-by-month MIST forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MIST could reach as high as $1.60, with a base case around $1.11 and support toward $1.01 — roughly 0% from $1.11. Price action looks broadly range-bound.
Expect MIST to range from $1.04 to $1.83 through 2027. The $1.34 average target implies a +21% move from current prices. That is up +21% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The MIST price prediction for 2028 points to an average of $1.44 (low $1.08, high $2.05) — a potential gain of +29% on today's $1.11. Momentum favours further upside here.
In 2029, MIST is projected to trade between $1.13 and $2.28, averaging $1.54 — a potential gain of +39% from today's $1.11. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Milestone Pharmaceuticals Inc.'s 2030 outlook centres on $1.82, within a $1.29 to $2.76 range. That is up +18% on the projected 2029 average. That marks a +64% change versus current levels. Momentum favours further upside here.
By 2031, MIST could reach as high as $3.42, with a base case around $2.19 and support toward $1.52 — roughly +97% from $1.11. Buyers look set to stay in control over this stretch.
Expect MIST to range from $1.74 to $4.10 through 2032. The $2.57 average target implies a +131% move from current prices. That is up +17% on the projected 2031 average. Momentum favours further upside here.
The MIST price prediction for 2033 points to an average of $2.86 (low $1.90, high $4.67) — a potential gain of +158% on today's $1.11. Buyers look set to stay in control over this stretch.
In 2034, MIST is projected to trade between $1.76 and $4.50, averaging $2.71 — a potential gain of +144% from today's $1.11. That is -5% versus the projected 2033 average. Momentum favours further upside here.
Milestone Pharmaceuticals Inc.'s 2035 outlook centres on $2.86, within a $1.83 to $4.83 range. That is up +6% on the projected 2034 average. That marks a +158% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, MIST could reach as high as $7.97, with a base case around $4.39 and support toward $2.56 — roughly +295% from $1.11. Momentum favours further upside here.
Expect MIST to range from $5.36 to $21.69 through 2050. The $10.78 average target implies a +871% move from current prices. That is up +146% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in MIST today (≈ 900.900901 MIST) could be worth
$9,712.82
+$8,712.82 (+871%) by 2050 · US Dollar
Based on the average projected MIST price of $10.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MISTwould be worth at today's price.
$1,000 invested in MIST on Jul 31, 2025 (≈ 689.65515 MIST) would be worth
$765.52
-$234.48 (-23.4%) today · 0.77× · US Dollar
Based on a MIST entry price of $1.45 vs. today's $1.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.16 | $956.9 | -4.3% |
| 1 month ago | $1.32 | $840.91 | -15.9% |
| 3 months ago | $1.87 | $593.58 | -40.6% |
| 6 months ago | $1.96 | $566.33 | -43.4% |
| 1 year ago | $1.45 | $765.52 | -23.4% |
| All time (5.0y) ago | $5.54 | $200.36 | -80.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MIST forecast.
Our base-case forecast reaches $2.20 around 2032.
Implied market cap at $2.20: $273.9M
The multi-year forecast shows a bullish trajectory, with the average price rising from $1.15 in 2026 to $1.82 in 2030 and $10.51 by 2050. ROI progresses from 0% in 2026 to 58.3% in 2030, then 276.6% by 2040 and 814% by 2050. Max price projections include $2.78 in 2030 and $7.88 in 2040, with $21.20 as the 2050 max, underscoring meaningful upside potential along the way while acknowledging the estimates are not guarantees and carry uncertainty.
Tap a question to reveal the answer.
In 2030 the forecast shows min $1.29, avg $1.82, max $2.78 with ROI 58.3% and sentiment BULLISH.
Forecasts indicate a bullish long-run trajectory, with average prices rising to $10.51 by 2050 and ROI reaching 814%. However, these are estimates and not guarantees.
The 2040 max price is $7.88 and the 2035 max is $4.81, so reaching $5 by 2040 is within the forecast range.
Current price is $1.15 and market cap is $129.48M.
RSI(14) is 40, SMA50 is $1.28, SMA200 is $1.76, with support at $1.04 and resistance at $1.34. The 30-day range runs from $0.919 to $1.44.
Milestone Pharmaceuticals Inc. Community Discussion
0Share your Milestone Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.